Ken Griffin Cin Cor Pharma, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$10.75 - $29.84 $1.65 Million - $4.58 Million
153,498 Added 345.73%
197,896 $2.43 Million
Q3 2022

Nov 14, 2022
BUY
$19.9 - $38.94 $883,520 - $1.73 Million
44,398 New
44,398 $1.46 Million

Others Institutions Holding CINC

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About CinCor Pharma, Inc.

CINC Quotes by TradingView
  • Ticker CINC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,764,300
  • Description
  • CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial...
More about CINC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email